DrugPatentWatch Database Preview
Drugs in Development Information for TAK-448
» See Plans and Pricing
What is the development status for investigational drug TAK-448?
TAK-448 is an investigational drug.
There have been 332 clinical trials for TAK-448.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
Summary for TAK-448
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2018-01-01) |
| Vendors | 2 |
Recent Clinical Trials for TAK-448
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration | Takeda | Phase 1 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants | Takeda | Phase 1 |
| A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults | Takeda | Phase 1 |
Clinical Trial Summary for TAK-448
Top disease conditions for TAK-448
Top clinical trial sponsors for TAK-448
US Patents for TAK-448
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
